Analysis: FDA's drug-safety restructure may be too cautious

08/11/2008 | RPM Report (free registration), The

A memorandum of agreement between the Office of New Drugs and the Office of Surveillance and Epidemiology could mean that the Center for Drug Evaluation and Research will favor OSE's perspective on regulatory action for close calls. Some industry experts fear the change may lead to a more cautious, conservative regulatory climate that unfairly weighs the risk side of the risk-benefit equation, according to this RPM Report analysis.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC